Literature DB >> 19297615

Potential use of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus expressed in Rachiplusia nu larvae as an immunogen for chickens.

Silvina Chimeno Zoth1, Evangelina Gómez, Juan Manuel Carballeda, Oscar Taboga, Elisa Carrillo, Analía Berinstein.   

Abstract

The hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus (NDV) was obtained as a recombinant antigen in Rachiplusia nu larvae. When it was used as an immunogen in chickens, a solid immune response, including neutralizing antibodies, was detected, demonstrating the potential use of this simple and economic strategy in the design of recombinant anti-NDV vaccines.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19297615      PMCID： PMC2681597          DOI： 10.1128/CVI.00432-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  20 in total

1.  Analysis of the protective effect of the haemagglutinin-neuraminidase protein in Newcastle disease virus infection.

Authors:  Y Nishino; M Niikura; T Suwa; M Onuma; B Gotoh; Y Nagai; T Mikami
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant.

Authors:  M E Boursnell; P F Green; J I Campbell; A Deuter; R W Peters; F M Tomley; A C Samson; P Chambers; P T Emmerson; M M Binns
Journal:  J Gen Virol       Date:  1990-03       Impact factor: 3.891

3.  Protective immunity against Newcastle disease: the role of antibodies specific to Newcastle disease virus polypeptides.

Authors:  D L Reynolds; A D Maraqa
Journal:  Avian Dis       Date:  2000 Jan-Mar       Impact factor: 1.577

4.  Avian paramyxovirus type 1 from pigeons: isolate characterization and pathogenicity after chicken or embryo passage of selected isolates.

Authors:  D J King
Journal:  Avian Dis       Date:  1996 Jul-Sep       Impact factor: 1.577

5.  Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens.

Authors:  J Taylor; C Edbauer; A Rey-Senelonge; J F Bouquet; E Norton; S Goebel; P Desmettre; E Paoletti
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

6.  Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses.

Authors:  K Karaca; J M Sharma; B J Winslow; D E Junker; S Reddy; M Cochran; J McMillen
Journal:  Vaccine       Date:  1998-10       Impact factor: 3.641

7.  Loss of N-linked glycosylation from the hemagglutinin-neuraminidase protein alters virulence of Newcastle disease virus.

Authors:  Aruna Panda; Subbiah Elankumaran; Sateesh Krishnamurthy; Zhuhui Huang; Siba K Samal
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Vaccination against Newcastle disease with a recombinant baculovirus hemagglutinin-neuraminidase subunit vaccine.

Authors:  E Nagy; P J Krell; G C Dulac; J B Derbyshire
Journal:  Avian Dis       Date:  1991 Jul-Sep       Impact factor: 1.577

9.  Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: the fusion protein derived from an avirulent strain had lower protective efficacy.

Authors:  N Kamiya; M Niikura; M Ono; C Kai; Y Matsuura; T Mikami
Journal:  Virus Res       Date:  1994-06       Impact factor: 3.303

10.  Locally produced mucosal IgG in chickens immunized with conventional vaccines for Newcastle disease virus.

Authors:  S Chimeno Zoth; E Gómez; E Carrillo; A Berinstein
Journal:  Braz J Med Biol Res       Date:  2008-04       Impact factor: 2.590
View more
  1 in total

1.  Rotavirus A-specific single-domain antibodies produced in baculovirus-infected insect larvae are protective in vivo.

Authors:  Silvia Gómez-Sebastián; Maria C Nuñez; Lorena Garaicoechea; Carmen Alvarado; Marina Mozgovoj; Rodrigo Lasa; Alan Kahl; Andres Wigdorovitz; Viviana Parreño; José M Escribano
Journal:  BMC Biotechnol       Date:  2012-09-07       Impact factor: 2.563
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.